Articles related to HEART ATTACK/MYOCARDIAL INFARCTION

A multicenter trial of 7,062 post-MI patients found that colchicine therapy, despite reducing C-reactive protein levels by 1.28 mg/L, did not significantly impact the composite outcome of cardiovascular death, recurrent MI, stroke, or unplanned revascularization over 3 years of follow-up.

A landmark analysis shows that physiology-guided complete revascularization reduced adverse outcomes by approximately 25% compared to culprit-only strategy across both STEMI and NSTEMI patients.

The ABYSS trial questions the safety of interrupting long-term beta-blocker treatment in patients with a history of uncomplicated myocardial infarction, finding that discontinuation was not noninferior to continuation.

A network meta-analysis of 24 trials (16,371 patients) found complete revascularization in myocardial infarction with multivessel disease reduced all-cause mortality by 15% compared to culprit-only revascularization, suggesting potential improved outcomes for this population.

A 70-year-old diabetic woman presented with epigastric pain and was diagnosed with a transmural anteroseptal myocardial infarction complicated by a left ventricular thrombus. Using an image, this case reinforces the critical importance of recognizing and managing late-presenting myocardial infarction.

The recent trial assessing CSL112’s role in enhancing cholesterol efflux capacity showed no significant reduction in cardiovascular events over one year among patients post-acute myocardial infarction, maintaining a safety profile consistent with placebo.